Inspired by patients.
Driven by science.

Key modelling data for UCB half-year results 2026

As of June 29, 2026

The UCB investor relations team has compiled the following items to assist capital market participants in preparation of the upcoming half-year results 2026 publication, scheduled for July 30, 2026.

Full-Year 2025 results

here

Updated Guidance 2026 (Website)

- 2026 Revenue: High single-digit % to low double-digit (in CER)
- 2026 adj. EBITDA growth: High single-digit % to mid-teens %
- FX impact: If 31-Dec-25 FX rates would persist through 2026: ~ -3 ppts on revenue growth and ~ -7 ppts on adjusted EBITDA growth

Note: These expectations exclude the potential impact of U.S. tariffs and any implications related to a Most Favoured Nation (MFN) pricing arrangement, as no final outcomes have been determined at this stage

Main drivers for 2026 performance

- Strong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®
- BIMZELX® access expansion & net pricing dynamics: Net pricing in H2 2025 benefited from several favorable factors, including accelerated conversion from bridge to paid and a higher share of uncontracted HS sales (fully reimbursed at 100%). The enhanced access as of 1 January 2026 will also influence net pricing dynamics.
- A BIMZELX® channel mix true-up of approximately €100M, recorded in H2 2025 but related to H1 2025, should be taken into account when comparing H1 2025 with H1 2026.
- BRIVIACT® loss of exclusivity and a perimeter effect from sale of non-core assets in 2025
- Continued investment behind 5 growth drivers
- Focused R&D execution including impact of Neurona acquisition (the upper end of our adjusted EBITDA growth guidance was narrowed from high-teens to mid-teens to absorb additional R&D and G&A costs linked to the acquisition which are expected to be largely incurred in the second half of the year).
- EVENITY® contribution

Consensus

Latest external VisibleAlpha consensus available on our website.

Recent deals and acquisitions

- Global license agreement for ATG-201, a B cell-depleting bispecific antibody with Antengene in March 2026
- Acquisition of Neurona Therapeutics, adding lead investigational asset, rezanecel, a neuronal cell therapy, being evaluated in phase I/II clinical trials for drug-resistant mesial temporal lobe epilepsy in March 2026. For additional information, please refer to our website.
- Acquisition of IMIDomics' Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs) and gaining access to one of the world's most comprehensive multi-omic datasets for immune mediated inflammatory diseases in May 2026
- Acquisition of Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers and adding Candid's lead asset, cizutamig, a bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, is currently in multiple phase 1 clinical studies across various autoimmune diseases in May 2026. For additional information, please refer to our website.

BIMZELX®

Reaching over 126,000 patients (as per last communication June 2026)

Exclusivity

- U.S. exclusivity (RDP = regulatory data protection): 2035 – plus potential patent term extension until 2037
- EU exclusivity: 2036
- Japan exclusivity: 2037

Formulary access: BIMZELX® covered and available for >80% of commercially insured lives– as per January 2026.

Reminder 2025 access:

- Psoriasis: 1st-line therapy with one of the top payers, while it obtained single-step and double-step edits for the other 2 top payers
- Rheumatology indications: single-step edit access with one leading payer and double-step edit access with the other two top payers
- HS: single-step edit with 2 of leading payers, third payer blocked

Additional 2026 access: +36 million additional lives covered (+25% versus 2025) for all indications at first line or double-step edit.

Data Presentation

- Three-year BIMZELX®(bimekizumab-bkzx) data at EHSF in HS February 2026
- Reported successful superiority head-to-head study versus risankizumab, an IL-23 inhibitor (BE BOLD) in May 2026. Data presented at EULAR conference in June 2026.

- BIMZELX data presentation on early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA, presented at EULAR in June 2026

EVENITY®

- EVENITY® is being developed and commercialized in collaboration with Amgen globally, as well as with Astellas in Japan. UCB books the EU sales and EU OPEX, Amgen books U.S., Japan and RoW sales, details on slide 33 in our Facts & Figures
- 50/50 net –contribution from Amgen split booked in "Other operating income".
- Amgen reported Q1/2026 net sales of U.S. $ 0.6bn (slide 6 in Amgen's Q1 presentation), +27% YoY growth.

FINTEPLA®

- U.S.: Loss of Exclusivity: Q4 2033
- New data presentation demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN in April 2026

RYSTIGGO®

Exclusivity

- U.S exclusivity: June 2037 (Patent Term Extension granted)
- EU exclusivity: 2034. European requests for extension (SPC) have granted in France, Italy and Spain with an expiry date of May 2038
- Japan exclusivity: 2037

Increased competitive pressure in the myasthenia gravis market in 2026 driven by the entry of new competitors.

ZILBRYSQ®

Exclusivity

- U.S. exclusivity (RDP = regulatory data protection): 2035 – plus potential patent term extension until 2037
- EU exclusivity: 2035. European requests for extension (SPC) have granted in France, Italy and Spain with an expiry date of May 2038
- Japan exclusivity: 2040

Increased competitive pressure in the myasthenia gravis market in 2026 driven by the entry of new competitors.

BRIVIACT®

- U.S.: Loss of exclusivity February 2026[1]
- EU: Loss of exclusivity August 2026[1]

Expected Loss of exclusivity impact: ~80% U.S. volume erosion and ~50% European volume erosion within 12 months

CIMZIA®

- Japan: off patent since 5 June 2026
- Current assumption for first possible biosimilar market entry: 2030 (no listing on clinicaltrials.gov as of today). Price pressure is increasing due to among others 340B rules in the U.S. (estimated in the high single-digit range) and is not expected to be offset by volume growth.

Pipeline & Regulatory update

- Full pipeline on our website
- European Commission approval of KYGEVVI™ for the treatment of thymidine kinase 2 deficiency (TK2d) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d) in March 2026
- Publication in the Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus in June 2026
- Data presentation at EULAR regarding Dapirolizumab Pegol showing Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus in June 2026

[1] Loss of exclusivity dates are indicative.

This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or

others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.